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Introduction {#sec1}
============

Type 2 immunity underpins numerous key homeostatic and immune processes in health and disease ([@bib41]). The type 2 cytokine environment is regulated at the tissue level by the release of epithelium-derived type 2 cytokines, including interleukin (IL)-25, thymic stromal lymphopoietin (TSLP), and the alarmin IL-33. These molecules elicit the production of type 2 effector cytokines from immune cells, which are fundamental for diverse functions, ranging from anti-helminth parasite immunity to allergic inflammation, wound healing responses, and metabolism ([@bib10], [@bib29]). Indeed, the tissue- and context-specific production of type 2 alarmins likely governs their downstream physiological functions. Adaptive type 2 immunity is driven by CD4^+^ T helper 2 (Th2) cells, which are the major source of type 2 inflammatory cytokines. However, CD4^+^ regulatory T (Treg) cells are increasingly associated with some type 2 inflammatory functions, such as wound healing and adipose tissue homeostasis ([@bib38], [@bib40]). The nature of the Treg cell association with type 2 immunity remains enigmatic and ranges from suppressive to synergistic. Indeed, Th2 and Treg cell subsets can respond directly to type 2 alarmins such as IL-33 and express overlapping transcriptional and functional programs ([@bib46], [@bib58]). While adaptive type 2 immune cells are rare in most tissues under homeostatic conditions, innate group 2 innate lymphoid cells (ILC2s) are tissue-resident cells and rapidly respond to type 2 alarmins by producing factors shared with both Th2 (IL-5 and IL-13) and Treg (Amphiregulin) cell function. The division of labor, and interactions, between ILC2s and adaptive type 2 immune cells remains a fundamental and unresolved question.

Roles for ILC2s directly regulating CD4^+^ T helper cell activation have been proposed recently ([@bib7], [@bib30], [@bib39], [@bib56]). MHCII-expressing ILC2s interact with antigen-specific T cells to instigate a dialog in which ILC2 and T cell crosstalk contributes to their mutual maintenance, expansion, and cytokine production ([@bib30], [@bib39]). ILC2s can also modulate T cell function, not by acting directly on naive CD4^+^ T cells but by collaborating with dendritic cells (DCs) to induce Th2 cell activation ([@bib17], [@bib18]). Notably, the importance of the local tissue environment is highlighted by the observation that the response to systemic antigen exposure is not sensitive to the absence of ILC2s ([@bib12]). In contrast to these models where ILC2 help initiates and maintains type 2 responses, it has been proposed that ILC2 and CD4^+^ T cell responses develop independently and that it is the tissue-localized exposure of these cells to locally produced cytokines that acts as a checkpoint in the activation of a type 2 response, rather than the interaction of these cells within the tissue ([@bib53]). Thus, the interplay between ILC2s and adaptive type 2 immune cells is likely to differ depending on anatomical location, activating signals, and temporal phase of the immune response.

In addition to the MHCII-mediated activation of helper T cells, the cognate interaction between the co-stimulatory molecule ICOSL on ILC2s and ICOS on T cells promotes Treg cell accumulation following IL-33 administration ([@bib33]). This is in addition to the ICOS-ICOSL autocrine signals that can enhance ILC2 proliferation ([@bib28]). An *in vitro* study also suggested the potential contribution for OX40 ligand (OX40L) expressed on ILC2s for the co-stimulation of T cells, though its role *in vivo* was not explored ([@bib7]). Ligation of OX40 by OX40L, encoded respectively by the genes *Tnfrsf4* and *Tnfsf4*, provides an important signal for the expansion or survival of Th2 cells, while less is understood about these effects on Treg cells ([@bib5], [@bib57]). OX40 is constitutively expressed at baseline on Treg cells and is induced on Th2 cells after T cell receptor (TCR)-mediated activation, while OX40L expression is reported on numerous immune cells but most notably on professional antigen-presenting cells such as DCs. Specifically, OX40L expression by DCs is important for effective Th2 cell responses to helminth-derived antigen ([@bib24]). OX40 binding to OX40L activates TNF receptor associated factor (TRAF) signaling pathways that synergize with TCR or cytokine-derived stimulation ([@bib5], [@bib57]).

Here we found that ILC2s express high levels of OX40L after exposure to IL-33. No other immune cells that we analyzed in the lung, including lung DCs, expressed OX40L *in vivo* in response to exogenously administered type 2 alarmins, including TSLP. OX40L expression on ILC2s was tissue restricted and correlated with local expansion of adaptive type 2 immune cells. ILC2s and OX40 were critical for tissue-specific IL-33-driven Th2 and Treg (preferentially GATA3^+^ Treg) cell responses. ILC2-targeted deletion of OX40L (*Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^) significantly impaired Th2 and Treg cell expansion following allergen exposure and *Nippostrongylus brasiliensis* helminth infection, with profound effects on overall type 2 inflammation. Thus, OX40L expression on ILC2s in response to epithelial cell-derived alarmins is a critical checkpoint for orchestrating adaptive type 2 responses.

Results {#sec2}
=======

ILC2 Are Critical for Regulating Adaptive Type 2 Immunity {#sec2.1}
---------------------------------------------------------

Airway exposure to the protease allergen papain results in IL-33-dependent accumulation of GATA3^+^ ILC2s and Th2 cells. The transcription factor GATA3 is critical for the development and function of type 2 cytokine-producing ILC2s and Th2 cells and is also expressed in a subset of Foxp3^+^ Treg cells associated with enhanced function and tissue residency ([@bib22], [@bib31], [@bib58], [@bib61]). We found that lung GATA3^+^ Treg cells were also strongly and preferentially induced by papain and IL-33, compared to GATA3^−^ Treg cells (17.7-fold compared to 7.1-fold increase, respectively) ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1D). GATA3^+^ Treg cells in control (PBS), papain-, or IL-33-exposed lungs were likely thymus derived, as indicated by co-expression of the transcription factor Helios and the vascular endothelial growth factor (VEGF) co-receptor neuropillin (Nrp)-1 ([Figures 1](#fig1){ref-type="fig"}A, 1B, and [S1](#mmc1){ref-type="supplementary-material"}E; [@bib52], [@bib60]). GATA3^+^ Treg cells also expressed more CTLA4 compared to GATA3^−^ Treg cells in naive and IL-33-treated mice ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}F). We purified Th2 cells, GATA3^+^ and GATA3^−^ Treg cells, and ILC2s from naive and IL-33-treated *Foxp3*^*EGFP-DTR/+*^*Gata3*^*hCD2/+*^ mice and performed RNA-seq gene expression analysis ([Figures 1](#fig1){ref-type="fig"}D, [S1](#mmc1){ref-type="supplementary-material"}G, and S1H, and [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). Gene expression data were consistent with flow cytometry findings. Moreover, we observed substantial overlap between ILC2s, GATA3^+^ Treg cells, and Th2 cells during homeostasis and after *in vivo* IL-33 stimulation, supporting the idea of shared regulatory and functional programs between these cells ([@bib40], [@bib46]).Figure 1ILC2s Are Required for Th2 and Treg Cell Response to IL-33(A--C) WT mice were treated with PBS or IL-33 (i.n., day 0 and 1) and analyzed on day 5 for Foxp3 and GATA3 expression in lung CD4^+^ T cells (A). Indicated populations (IL-33-treated shown) were subsequently analyzed for expression of Helios and neuropilin-1 (Nrp-1) (B) and CTLA4 (C).(D) RNA-seq was performed on lung Foxp3^egfp+^GATA3^hDC2+^ and Foxp3^egfp+^GATA3^hDC2−^ Treg cells, Foxp3^egfp−^GATA3^hDC2+^ Th2 cells, and ILC2s on day 5 after treatment with PBS or IL-33 (i.n., day 0 and 1). Shown is a Venn diagram of transcripts expressed in each cell population (\>10 RPKM).(E) Mice were treated with IL-33 and 2W1S-peptide as indicated (i.n., day 0 and 1), followed by quantification of 2W1S-Tetramer^+/−^ Foxp3^+^GATA3^+^ Treg cells and Foxp3^−^GATA3^+^ Th2 cells in the lung on day 5.(F) Mice were treated with IL-33 (i.n., day 0 and 1) followed by quantification of Foxp3^+^GATA3^+\ and\ −^ Treg cells and Foxp3^−^GATA3^+^ Th2 cells in the lung on day 5.(G) PBS- or diphtheria toxin (DTX)-treated ICOS-T mice were administered with IL-33 and 2W1S-peptide as indicated (i.n., day 0 and 1), followed by quantification of 2W1S-Tetramer^+/−^ Foxp3^+^GATA3^+^ Treg and Foxp3^−^GATA3^+^ Th2 cells in the mLN on day 5.Bar graphs indicate mean (±SEM). (A)--(C), three repeat experiments, mean percent gated population in (A); (D), single experiment; (E), ANOVA, three repeat experiments; (F), ANOVA, two repeat experiments; (G), ANOVA, three repeat experiments. ns = not significant, ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, ^∗∗∗^p ≤ 0.001, ^∗∗∗∗^p ≤ 0.0001. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

IL-33 is known to have direct effects on Treg cells, which express its receptor ST2 ([Figure S1](#mmc1){ref-type="supplementary-material"}I; [@bib43]). However, we observed no significant proliferative advantage of ST2^+^ over ST2^*−*^ Treg cells after IL-33-induced expansion as assessed by Ki67 staining, or in an adoptive transfer experiment of mixed WT and *Il1rl1*^*−/−*^ CD4^+^ T cells, thus suggesting that an alternative mechanism contributes to IL-33-mediated Treg cell expansion ([Figures S1](#mmc1){ref-type="supplementary-material"}J--S1M). Given that ILC2s can regulate Th2 cells *in vivo* via direct ([@bib7], [@bib30], [@bib39]) and indirect ([@bib17], [@bib18]) mechanisms and can regulate Treg cells via an ICOS-ICOSL interaction *in vitro* ([@bib33]), we tested whether IL-33-driven Treg cell expansion was ILC2 dependent in two models of ILC2 deficiency ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2F). The 2W1S peptide immunogen, co-administered with IL-33, was used to track antigen-specific CD4^+^ T cell responses using the 2W1S:I-A^b^ MHCII tetramer ([@bib35]). We found that both antigen-specific and non-specific (2W1S:tetramer^+\ and^ ^*−*^) Treg and Th2 cell responses were impaired in ILC2-deficient *Il7ra*^*Cre/+*^*Rora*^*fl/fl*^ mice ([Figures 1](#fig1){ref-type="fig"}E, [S2](#mmc1){ref-type="supplementary-material"}B, and S2C). As a subset of CD4^+^ T cells can also express *Rora*, we generated *Cd4*^*Cre/+*^*Rora*^*fl/fl*^ mice, which showed no defect in type 2 immune-mediated expulsion of *N. brasiliensis*, or in Th2 or Treg cell numbers after allergen or IL-33 challenge, supporting our previous *in vitro* results ([Figures 1](#fig1){ref-type="fig"}F, [S2](#mmc1){ref-type="supplementary-material"}D, and S2E; [@bib16], [@bib59]). Additionally, using a separate model of ILC2 deletion in diphtheria toxin (DTx)-treated ICOS-T mice ([@bib39]), we observed a similar defect in GATA3^+^ Treg and Th2 cell responses after IL-33 + 2W1S peptide administration ([Figures 1](#fig1){ref-type="fig"}G and [S2](#mmc1){ref-type="supplementary-material"}F--S2H). As reported previously, ILC3s may also be impaired by DTx in *Icos*^*fl-DTR-fl/+*^*Cd4*^*Cre/+*^ (ICOS-T) mice, although lung ILC3s are sparse and not substantially affected by IL-33-driven inflammation ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H). Further, to investigate a potential role for B cells, we injected B cell-deficient *Ighm*^*−/−*^ (μMT) mice with IL-33, followed by analysis for Th2 and Treg cells. We observed no significant difference in IL-33-driven Treg and Th2 cell expansion in the lungs of μMT compared to WT mice ([Figures S2](#mmc1){ref-type="supplementary-material"}I and S2J). Moreover, immunofluorescence microscopy analysis of IL-33-treated WT mice showed co-localization of Treg cells and ILC2s in the lungs ([Figure S2](#mmc1){ref-type="supplementary-material"}K), as reported previously ([@bib33]). Thus, ILC2s are critical for allergen- and IL-33-induced expansion of Th2 cells and GATA3^−^ and GATA3^+^ Treg cells.

OX40 Is Required for Expansion of Adaptive Type 2 Immunity by IL-33 {#sec2.2}
-------------------------------------------------------------------

We investigated possible cell-to-cell interactions that may influence IL-33-driven Th2 and Treg cell expansion and first focused on T cell co-receptors. Gene expression analysis for the tumor necrosis factor (TNF) receptor-superfamily was conducted using lung ILC2s and other IMMGEN ([@bib20]) immune cell datasets ([Figure 2](#fig2){ref-type="fig"}A). We observed high expression of *Tnfrsf4* (OX40), an important T cell co-stimulatory receptor ([@bib5]), on Treg and activated CD4^+^ T cells. We confirmed that OX40 was expressed on lung GATA3^+^ and GATA3^−^ Treg cells in PBS, papain-, or IL-33-stimulated mice, but not Foxp3^−^GATA3^−^CD4^+^ T cells ([Figures 2](#fig2){ref-type="fig"}B, 2C, and [S3](#mmc1){ref-type="supplementary-material"}A). OX40 was also expressed on a smaller proportion of Th2 cells after IL-33 administration ([Figure 2](#fig2){ref-type="fig"}B). We hypothesized that OX40 may be important for mediating the IL-33-driven expansion of Th2 and Treg cells. Using *Tnfrsf4*^*−/−*^ mice, we determined that the OX40 co-stimulatory molecule was essential for IL-33-mediated Treg cell expansion in the lungs ([Figures 2](#fig2){ref-type="fig"}D--2F). We observed similar requirements of OX40 for the development of lung Th2 cells in response to IL-33, while ILC2 expansion was unaffected ([Figure S3](#mmc1){ref-type="supplementary-material"}B). *Tnfrsf4*^*−/−*^ mice also showed a similar defect in adaptive type 2 immunity after intranasal administration of papain ([Figures 2](#fig2){ref-type="fig"}G--2I). Thus, OX40 signaling is critical for the induction of IL-33-dependent adaptive type 2 immunity.Figure 2OX40 Is Critical for Th2 and Treg Cell Response to IL-33 and Papain(A) TNFRSF gene expression was analyzed in the indicated immune cell populations using IMMGEN and naive lung ILC2 microarray data.(B and C) OX40 expression was analyzed on lung GATA3^+^ and GATA3^−^ Treg and Th2 cells on day 5 from WT mice treated with PBS, papain, or IL-33 (i.n., day 0 and 1). Fluorescence minus one (FMO) control was used to establish gating threshold. Percent OX40^+^ cells were calculated in the indicated populations and treatments and compared to Foxp3^−^GATA3^−^ (DN) CD4^+^ T cells.(D--F) Lung GATA3^+^ and GATA3^−^ Treg and Th2 cells were quantified from WT and *Tnfrsf4*^*−/−*^ mice on day 5 after IL-33 treatment (i.n., day 0 and 1).(G--I) Lung GATA3^+^ and GATA3^−^ Treg and Th2 cells were quantified from WT and *Tnfrsf4*^*−/−*^ mice on day 5 after papain (Pap) treatment (i.n., day 0 and 1).Bar graphs indicate mean (±SEM). (A), two independent datasets per group; (B) and (C), ANOVA, two repeat experiments; (D)--(F), ANOVA, two repeat experiments; (G)--(I), ANOVA, two repeat experiments. ^∗∗∗^p ≤ 0.001, ^∗∗∗∗^p ≤ 0.0001. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

ILC2s Selectively Express OX40L in Response to IL-33 {#sec2.3}
----------------------------------------------------

Next, we identified the critical OX40L-expressing cells by analyzing gene expression for *Tnfsf4* and other TNF superfamily ligand transcripts. We found that *Tnfsf4* (OX40L) gene expression was highest in naive lung ILC2s and substantially lower in any of the other tested immune cells ([Figure 3](#fig3){ref-type="fig"}A). To confirm these findings, we assessed OX40L expression on lung immune cells in mice stimulated intranasally with IL-25, IL-33, TSLP, papain, LPS, or PBS. While control mice did not show OX40L protein expression on any cells that we analyzed (ILC2s, B cells, CD4^+^ and CD8^+^ T cells, DCs, Macs, and NK cells), only ILC2s showed a significant induction of OX40L surface expression upon IL-33, papain, and to a lesser degree IL-25, stimulation ([Figures 3](#fig3){ref-type="fig"}B, 3C, and [S4](#mmc1){ref-type="supplementary-material"}A--S4C). Moreover, lung DCs from adult mice failed to induce OX40L expression in response to intranasal administration of any of these stimuli, including two separate TSLP formulations and anti-CD40 mAb treatment ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Also, OX40L^+^ ILC2s significantly outnumbered OX40L^+^ DCs after IL-33 administration and also exhibited higher intensity surface staining of OX40L ([Figure S4](#mmc1){ref-type="supplementary-material"}E). Notably, human ILC2s also strongly induced OX40L after IL-33 stimulation ([Figure S4](#mmc1){ref-type="supplementary-material"}F). Additionally, IL-33 administration to mice by intranasal (i.n.) or intraperitoneal (i.p.) routes rapidly (day 2) increased Treg cell proliferation in the lung but not mediastinal lymph node (mLN), while ILC2s at both sites were activated and expressed ST2 ([Figures 3](#fig3){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}G). When we measured the expression of OX40L on ILC2s after IL-33 administration, we observed that lung ILC2s expressed OX40L, while mLN ILC2s and ILC3s did not ([Figure 3](#fig3){ref-type="fig"}E). Lastly, proliferation of total CD4^+^ T cells was not significantly affected in either lung or mLN by IL-33 administration ([Figure S4](#mmc1){ref-type="supplementary-material"}H). This led us to speculate that IL-33-driven local expansion of adaptive type 2 immune cells is governed by ILC2-restricted OX40L expression.Figure 3ILC2s Are the Main OX40L-Expressing Cell in Response to IL-33(A) TNFSF gene expression was analyzed in the indicated immune cell populations using IMMGEN and naive lung ILC2 microarray data.(B) OX40L expression was measured on lung DCs or ILC2s in WT mice on day 2 after treatment with PBS or IL-33 (i.n., day 0 and 1).(C) The percentage of OX40L^+^ ILC2s (top) and DCs (bottom) was measured on day 2 in response to the indicated stimuli (i.n., day 0 and 1).(D) The percent of Ki67^+^ ILC2s and Treg cells was measured on day 2 after treatment with PBS or IL-33 (day 0 and 1).(E) OX40L expression was measured on ILC2s and ILC3s in the lung or mLN on day 2 after PBS or IL-33 treatment (i.n., day 0 and 1).Numbers in (B) and (E) indicate percent (mean ± SD) gated populations. (A), two independent datasets per group; (B), three repeat experiments; (C), ANOVA, two repeat experiments; (D), ANOVA, two repeat experiments; (E), two-tailed Student's t test, two repeat experiments. ^∗∗∗^p ≤ 0.001, ^∗∗∗∗^p ≤ 0.0001. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

OX40L Expression by ILC2s Correlates with Tissue-Specific T Cell Proliferation {#sec2.4}
------------------------------------------------------------------------------

To further ascertain the importance of OX40L expression by ILC2s following IL-33-driven induction of adaptive type 2 immunity, we crossed *Tnfsf4*^*fl/fl*^ mice with *Il7r*^*Cre/+*^ mice. Although other immune cells such as ILC3s and CD4^+^ T cells also express IL7Rα, we did not observe OX40L expression in these populations. Efficient deletion of OX40L on ILC2s was achieved in *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice, as indicated by reduced expression of OX40L on lung ILC2s after IL-33 administration ([Figures 4](#fig4){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A). Next, we asked whether ILC2-targeted deletion of OX40L influenced the IL-33-driven effects on adaptive type 2 immunity. We administered IL-33 to *Il7r*^*Cre/+*^, *Il7r*^*Cre/+*^*Rora*^*fl/fl*^, and *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice on days 0 and 1, followed by analysis on day 5. Notably, *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice failed to induce Th2 cells and GATA3^+^ and GATA3^−^ Treg cell responses in the lungs after treatment ([Figures 4](#fig4){ref-type="fig"}B--4D). The observed defect produced a phenotype similar to naive control or IL-33-treated *Il7r*^*Cre/+*^*Rora*^*fl/fl*^ mice. We subsequently investigated lung, large intestine, and perigonadal adipose tissue for the IL-33/ILC2/OX40L-driven effect on adaptive type 2 immunity. Here we noted clearly divergent phenotypes with OX40L expression induced only on lung and adipose tissue-resident ILC2s but not in the intestine ([Figure 4](#fig4){ref-type="fig"}E). Nevertheless, ILC2 and ILC3 numbers in *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice were similar to those in control mice ([Figures 4](#fig4){ref-type="fig"}F, [S5](#mmc1){ref-type="supplementary-material"}B, and S5D). Moreover, only these two sites exhibited IL-33-driven expansion of Th2 cells and GATA3^+^ and GATA3^−^ Treg cells ([Figures 4](#fig4){ref-type="fig"}G and [S5](#mmc1){ref-type="supplementary-material"}C). Importantly, ILC2-targeted deletion of OX40L phenocopied ILC2 deficiency. This indicated the critical nature of OX40L expression by ILC2s for establishing tissue-specific adaptive type 2 immunity.Figure 4OX40L Expression by ILC2s Is Essential for Tissue-Specific Adaptive Immune Response to IL-33(A) OX40L expression on lung ILC2s in the specified genotypes on day 2 after IL-33 administration (i.n., day 0 and 1).(B--D) Lung GATA3^+^ and GATA3^−^ Treg and Th2 cell numbers were quantified on day 5 after treatment with PBS or IL-33 (i.n., days 0 and 1).(E--G) OX40L expression on ILC2s was measured in the indicated tissues (L. int., large intestine) after treatment with PBS or IL-33 (days 0 and 1) on day 2 (E), while the number of ILC2s (F) and GATA3^+^ Treg cells was quantified on day 5 (G).Numbers in (A) and (E) indicate percent (mean ± SD) gated populations. Bar graphs indicate mean (±SEM). (A), three repeat experiments; (B)--(D), ANOVA, two repeat experiments; (E)--(G), ANOVA, two repeat experiments. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, ^∗∗∗∗^p ≤ 0.0001. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

OX40L on ILC2s Is Specifically Required for IL-33-Driven Effects on Adaptive Type 2 Immunity {#sec2.5}
--------------------------------------------------------------------------------------------

OX40L is reported on other IL7Rα^+^ cell types, including CD4^+^ T cells and RORγt^+^ ILC3s, and is widely described on CD11c^+^ DCs ([@bib25], [@bib57]). While we observed only OX40L on ILC2s after IL-33 stimulation, IL7Rα^Cre^-driven deletion of OX40L is not entirely ILC2 specific. To better control for possible OX40L signaling contributions from other immune cells, we intercrossed *Tnfsf4*^*fl/fl*^ mice with *Itgax*^*Cre*^, *Rorc*^*Cre/+*^, and *Cd4*^*Cre/+*^ mice to further exclude non-ILC2-driven effects. As before, we administered IL-33 to the indicated control or OX40L-targeted mice, followed by analysis for induction of adaptive type 2 immunity. While ILC2-deficient and ILC2-targeted OX40L-deficient *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice both failed to induce GATA3^+^ Treg, GATA3^−^ Treg, and Th2 cells, mice with DC-targeted (*Itgax*^*Cre*^*Tnfsf4*^*fl/fl*^), ILC3-targeted (*Rorc*^*Cre/+*^*Tnfsf4*^*fl/fl*^), and CD4^+^ T cell-targeted (*Cd4*^*Cre/+*^*Tnfsf4*^*fl/fl*^) OX40L deletion showed no deficit compared to OX40L-sufficient control mice ([Figures 5](#fig5){ref-type="fig"}A--5C). Finally, we generated *Il7r*^*Cre/+*^*Rora*^*fl/fl*^ + *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mixed bone marrow (BM) chimeric mice, in which ILC2s are OX40L deficient, to further investigate the role of OX40L on ILC2s ([Figure S6](#mmc1){ref-type="supplementary-material"}D). The mixed BM chimeras showed a significant reduction, similar to ILC2-deficient BM chimeric mice, in GATA3^+^ and GATA3^−^ Treg cells after IL-33 administration compared to control mice ([Figures 5](#fig5){ref-type="fig"}D and 5E). Thus, OX40L expression on ILC2s is essential for IL-33-driven activation of adaptive type 2 immunity.Figure 5OX40L-Driven Response to IL-33 Is Restricted to ILC2s(A--C) Lung GATA3^+^ and GATA3^−^ Treg cells and Th2 cells were quantified on day 5 in the specified genotypes, treated with PBS or IL-33 (i.n., days 0 and 1).(D and E) Bone marrow and mixed-bone marrow chimeric mice were created with the indicated genotypes. 6 to 7 months after bone marrow transfer, mice received IL-33 (i.n., days 0 and 1) followed by quantification of lung GATA3^+^ Treg (D) and GATA3^−^ Treg (E) cells on day 5.Bar graphs indicate mean (±SEM). ANOVA, two repeat experiments. ns = not significant, ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, ^∗∗∗^p ≤ 0.001, ^∗∗∗^p ≤ 0.0001. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

IL-33-ILC2-OX40L Pathway Is Critical for Allergen-Induced Adaptive Type 2 Immunity {#sec2.6}
----------------------------------------------------------------------------------

Protease allergens are potent inducers of IL-33 in the airways, which is a central mechanism by which they drive innate and adaptive type 2 immunity ([@bib15], [@bib19]). In addition to Th2 cells, we investigated the role of IL-33 in mediating allergen-induced Treg cell responses in the lungs. Administration of the protease allergen papain led to an induction of lung GATA3^+^ and GATA3^−^ Treg cells on day 5 in WT mice ([Figures 6](#fig6){ref-type="fig"}A, 6B, and [S7](#mmc1){ref-type="supplementary-material"}A). Papain-induced Treg cell responses were significantly reduced in *Il33*^*cit/cit*^ (*Il33*^*−/−*^) or *Il1rl1*^*−/−*^ mice ([Figures 6](#fig6){ref-type="fig"}A and 6B), indicating the importance of IL-33 for mediating allergen-induced expansion of Treg cells in the airways. As expected, Th2 cells were also significantly reduced in *Il33*^*cit/cit*^ or *Il1rl1*^*−/−*^ mice compared to WT controls ([Figures 6](#fig6){ref-type="fig"}C and 6D). We then investigated the role of ILC2-expressed OX40L for driving adaptive type 2 immunity in the lungs after papain exposure. We observed a failure of Th2 cells and GATA3^+^ and GATA3^−^ Treg cells to develop in the lungs of *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice ([Figures 6](#fig6){ref-type="fig"}A--6D). Next we exposed *Il7r*^*Cre/+*^, *Il7r*^*Cre/+*^*Rora*^*fl/fl*^, and *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice to repeat exposures of papain after initial sensitization, followed by analysis of the lungs for multiple parameters of innate and adaptive type 2 inflammation ([Figure S7](#mmc1){ref-type="supplementary-material"}B). On day 24 we found that *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice had significant reductions in Th2 cells and GATA3^+^ and GATA3^−^ Treg cells compared to *Il7r*^*Cre/+*^ controls ([Figures S7](#mmc1){ref-type="supplementary-material"}C--S7E). These reductions were similar to those observed in ILC2-deficient mice. We also observed significant reductions in lung eosinophilia ([Figure 6](#fig6){ref-type="fig"}E) and M2 polarization by lung macrophages as assessed by intracellular staining for RELMα ([Figures 6](#fig6){ref-type="fig"}F and 6G; [@bib37]). We further investigated whether OX40L expression by ILC2s may influence adaptive type 2 immunity to another allergen. Administration of *Alternaria alternata* extract promoted an increase in lung Th2 cells, but also GATA3^+\ and\ --^ Treg cells by day 9, that was impaired in *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice ([Figure 6](#fig6){ref-type="fig"}H). Moreover, we found that the *A. alternata* induced increase in serum IgE was reduced in *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice ([Figure 6](#fig6){ref-type="fig"}I). Interestingly, CD11c^Cre^ targeted OX40L deletion also resulted in reduced Th2 and Treg cells after *A. alternate*-induced airway inflammation ([Figure S7](#mmc1){ref-type="supplementary-material"}F), suggesting that both DC- and ILC2-derived OX40L contribute to the response. Thus, ILC2-expressed OX40L is critical for mediating ILC2-induced innate and adaptive type 2 inflammation to allergen exposure in an IL-33-dependent pathway.Figure 6OX40L on ILC2s Orchestrates Adaptive Type 2 Immunity to Allergens(A--D) Mice of the specified genotypes were treated with PBS or papain (Pap) (i.n., day 0 and 1), followed by quantification of lung Th2, GATA3^+^ Treg, and GATA3^−^ Treg cells on day 5 (A--C). Whole lung cell suspensions were re-stimulated with PMA and ionomycin, followed by quantification of IL-13^+^ Th2 cells by intracellular staining (D).(E--G) Mice were treated with papain on days 0, 1, 14, and 21, followed by quantification on day 24 of lung eosinophils (E), and detection (F) and quantification (G) of RELMα^+^ M2 alveolar (CD45^+^SiglecF^+^CD11c^+^CD11b^−^F4/80^+^) macrophages (MΦ).(H and I) Mice were treated with *A. alternata* (*A.alt*) (i.n., days 0 and 1), followed by quantification on day 9 of lung Th2, GATA3^+^ Treg, and GATA3^−^ Treg cells (H) and serum IgE concentration (I).Bar graphs indicate mean (±SEM). (A)--(D), ANOVA, two repeat experiments; (E), ANOVA, three repeat experiments; (F) and (G), ANOVA, two repeat experiments, representative gate shown in (F); (H) and (I), ANOVA, two repeat experiments. ^∗∗^p ≤ 0.01, ^∗∗∗^p ≤ 0.001, ^∗∗∗∗^p ≤ 0.0001. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

OX40L-Expressing ILC2s Are Essential for Adaptive Type 2 Immunity to Helminth Challenge {#sec2.7}
---------------------------------------------------------------------------------------

To interrogate the importance of the ILC2-OX40L axis in complex immune challenges, we used the prototypical type 2 immunity-inducing parasitic helminth, *N. brasiliensis*, which traffics through the lung after infection, inducing profound and prolonged type 2 inflammation ([@bib32]). Besides Th2 cells, Treg cells are known to play an important role for wound healing and tissue remodeling of the lung ([@bib3], [@bib51]). First, we characterized the adaptive type 2 immune response in the lungs of mice on day 28 after *N. brasiliensis* infection and observed substantial increases in GATA3^+^ and GATA3^−^ Treg cells and Th2 cells in control mice ([Figures 7](#fig7){ref-type="fig"}A--7C and [S7](#mmc1){ref-type="supplementary-material"}G). By contrast, *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice exhibited a failure of the lung Th2 cells and GATA3^+^ and GATA3^−^ Treg cells to expand, with numbers remaining similar to uninfected control mice. Notably, this impairment mirrored that measured in *Il7r*^*Cre/+*^*Rora*^*fl/fl*^ mice ([Figures 7](#fig7){ref-type="fig"}A--7C). Lung histology demonstrated that *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice had reduced histological features of inflammation compared to infected control mice ([Figure 7](#fig7){ref-type="fig"}D), again similar to those in *Il7r*^*Cre/+*^*Rora*^*fl/fl*^ mice. While infected control mice mounted a prolific eosinophil response, we observed an impairment in *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice to induce eosinophilia in the lung ([Figure 7](#fig7){ref-type="fig"}E) or BAL ([Figure 7](#fig7){ref-type="fig"}F). Similar impairments were observed when we quantified RELMα^+^ M2 polarized lung macrophages ([Figure 7](#fig7){ref-type="fig"}G) and BAL concentrations of IL-4 and IL-5 ([Figure 7](#fig7){ref-type="fig"}H), while IL-13^+^ Th2 cells were also significantly reduced in the lungs of *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ compared to control mice ([Figure 7](#fig7){ref-type="fig"}I). Moreover, by day 28 after infection, we observed a reduction of adaptive type 2 CD4^+^ T cells in the mLN, and total lung IgE concentration of both infected *Il7r*^*Cre/+*^*Rora*^*fl/fl*^ and *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice compared to controls ([Figures 7](#fig7){ref-type="fig"}J--7M). Furthermore, at 5 days after *N. brasiliensis* infection, we observed a modest increase in worm numbers of *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice compared to control mice ([Figure 7](#fig7){ref-type="fig"}N). Of note, while absolute cell numbers were reduced, we observed no reduction in Th2 cell frequency in infected *Il7r*^*Cre/+*^*Rora*^*fl/fl*^ or *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice compared to control mice. Moreover, no significant differences were observed in type 1 immunity (IFN-γ production), NK cells, and CD8^+^ T cells of both *Il7r*^*Cre/+*^*Rora*^*fl/fl*^ and *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice compared to controls after infection ([Figures S7](#mmc1){ref-type="supplementary-material"}H--S7K). Thus, these results indicate that the IL-33/ILC2/OX40L axis is broadly important for orchestrating innate and adaptive type 2 immunity following helminth challenge.Figure 7ILC2-Expressed OX40L Is Essential for Airway Adaptive Type 2 Immune Response to Helminth InfectionMice of the specified genotypes were infected with *Nippostrongylus brasiliensis* (*N.b.*) on day 0, followed by analysis on day 28 (or day 5) of:(A--C) Lung Th2, GATA3^+^ Treg, and GATA3^−^ Treg cell numbers.(D) Representative lung histology (Mason's trichrome).(E and F) Lung (E) and bronchoalveolar lavage (F) eosinophil numbers.(G) Lung RELMα^+^ M2 macrophage (MΦ) numbers.(H) Bronchoalveolar lavage IL-4 and IL-5 cytokine concentrations.(I) Whole lung cell suspensions were re-stimulated with PMA and ionomycin, followed by quantification of lung IL-13^+^ Th2 cell numbers by intracellular staining.(J--L) Mediastinal lymph node Th2, GATA3^+^ Treg, and GATA3^−^ Treg cell numbers.(M) Concentration of IgE present in lung homogenate, normalized for total protein content.(N) Intestinal worm burden of indicated mouse genotypes 5 days post infection.Bar graphs indicate mean (±SEM). (A)--(C), ANOVA, three repeat experiments; (D), two repeat experiments; (E)--(I), ANOVA, two repeat experiments; (J)--(L), ANOVA, three repeat experiments; (M), ANOVA, two repeat experiments; (N), two-tailed Student's t test, two pooled experiments. ns = not significant, ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, ^∗∗∗^p ≤ 0.001, ^∗∗∗∗^p ≤ 0.0001. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

The potential role of ILC2s as key potentiators of immune activation, performing as intermediaries between the damaged epithelium and the adaptive immune system, is currently an important and unresolved question. While previous studies have started to reveal mechanisms by which ILC2s can influence Th2 cell priming ([@bib17], [@bib18], [@bib30], [@bib39]), the continued importance of ILC2s in the presence of adaptive type 2 immunity is unclear ([@bib53], [@bib55]), especially because Th2 and Treg cells may also be directly activated by IL-33 ([@bib14], [@bib43]).

Our results using ILC2-deficient mouse models indicated that IL-33-driven expansion of Th2 and Treg cells was dependent on ILC2s. As RORα is also expressed by T cells, it has been suggested that deletion of *Rora* in lymphocytes may directly alter T cell responses. Significantly, using *Cd4*^*Cre/+*^*Rora*^*fl/fl*^ mice, we excluded the possibility that *Rora* deletion results in CD4^+^ T cell-intrinsic effects that diminish adaptive immunity. Indeed, we demonstrated that mice whose T cells lack RORα mounted equivalent type 2 adaptive immune responses to parasitic worm infection, papain allergen, and IL-33 as RORα-sufficient T cell controls.

To further elucidate the mechanism by which ILC2s can orchestrate Th2 and Treg cell responses, we identified costimulatory molecules that were counter-expressed on ILC2s and T cells. Gene expression data highlighted the potential importance of OX40/OX40L interactions, which have been linked previously with the development of Th2 cell responses ([@bib5], [@bib57]). OX40 is expressed on memory T cells after TCR-mediated recall responses ([@bib5]) and is also associated with Treg cell homeostasis and function ([@bib50]). Additionally, we discovered that OX40L, which has been reported on other immune cells in response to type 2 alarmins ([@bib5], [@bib57]), was increased on lung ILC2s in response to IL-33.

Notably, we were unable to detect OX40L on lung-resident dendritic cells, or other lung cell populations, even after treating mice with TSLP. Although OX40L mRNA expression is reported in many models of type 2 inflammation, and OX40L protein expression can be induced on *in vitro* cell-cultured mouse and human DCs stimulated with various cytokines (e.g., TSLP) and antigens, the cellular expression of OX40L protein *in vivo* remains relatively opaque. Nevertheless, while alarmin stimulation did not induce OX40L expression on lung-resident DCs, our study with *A. alternata*-induced lung inflammation clearly showed a role for OX40L expression by CD11c^+^ cells, confirming previous findings of impaired Th2 cell priming of OX40L-deficient DCs ([@bib24]). As we did not observe OX40L on ILC2s in the draining mLNs, it appears that separate functions of OX40L are enforced by distinct cell types.

Moreover, while IL-33-mediated expansion of Th2 and Treg cells may involve an antigen-independent mechanism solely reliant on ILC2s, more complex antigens such as *A. alternata* and house dust mite activate multiple cellular targets, including DCs ([@bib6]). Similarly, neonatal mouse DCs in the lung transiently express OX40L, suggesting differential expression patterns dependent on developmental stage ([@bib6]). Thus, ILC2- and DC-expressed OX40L may play partially compensatory roles and further study is required to resolve the complexity of how differing temporal expression, tissue environment, and the nature of the antigen encountered may influence the induction of these pathways in protecting the host.

We observed that OX40-deficient mice and mice with a conditional deletion of OX40L (*Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^) had significantly impaired Th2 and Treg cell responses following IL-33 administration, a phenotype similar to ILC2-deficient mice. Furthermore, mixed BM chimeric mice, in which only ILC2s were OX40L deficient, also failed to induce Treg cells following IL-33 administration. By contrast, conditional deletion of OX40L from T cells, dendritic cells, and ILC3s resulted in normal IL-33-induced responses. The deletion of OX40L from ILC2s also curtailed the onset of type 2 immunity in the lungs of mice administered papain allergen or infected with parasitic helminths. Thus, OX40L expression on ILC2s, but not DCs, is essential for the robust onset of IL-33-induced type 2-mediated lung inflammation.

Previous studies have demonstrated that OX40- and OX40L-deficient mice fail to develop type 2 responses characteristic of allergic lung inflammation ([@bib21], [@bib23]) and showed that OX40L-deficient (*Tnfsf4*^*−/−*^) mice were less efficient at responding to *Heligmosomoides polygyrus* ([@bib8]). We now establish ILC2s, through their tissue-specific expression of OX40L in response to IL-33, as critical players in the local expansion of OX40-expressing Th2 and Treg cells and the initiation and maintenance of robust type 2 responses in the lung. The co-induction of Th2 and Treg cells via the same signaling pathways may serve to limit allergic inflammation, as indicated by the suppressive role of Treg cells on Th2 cell-driven lung inflammation ([@bib48]), while also promoting wound healing such as in response to helminth-induced damage ([@bib41]). Indeed, we showed that *N. brasiliensis*-induced adaptive type 2 immunity, important for lung damage repair ([@bib3]), is dependent on OX40L expression on ILC2s. Accordingly, we observed a profound reduction in eosinophils, alternatively activated Macs, and type 2 effector cytokines. Importantly, ILC2s and Treg and Th2 cells were detectable in normal numbers at baseline in *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice, and type 1 immunity was unaffected after immune challenge.

OX40L can be regulated in an age- and tissue-specific manner and can be induced on a range of immune cells under various inflammatory conditions ([@bib5], [@bib6], [@bib57]). The availability of a conditional OX40L allele will be of significant importance in continuing to identify critical cellular sources of OX40L in mouse models. For example, whether OX40L on ILC2s, in addition to DCs, is also instructive during neonatal establishment of persistent Th2 and Treg cells in response to IL-33 is unknown but of critical importance ([@bib6], [@bib13], [@bib42], [@bib47]). In adult mice, however, we implicated OX40L expression on ILC2s in diverse lung pathologies. Other cellular signaling molecules such as ICOSL and PD-1L may also influence cross-talk between ILC2s and T cells, although the magnitude of the ILC2-specific effect and broad expression of these ligands on other immune cells suggests a different role compared to OX40L ([@bib33], [@bib45]). The tissue-specific OX40L expression profile of ILC2s was an intriguing finding that warrants further investigation. Environmental cues or developmental programs may influence the response and/or sensitivity of ILC2s to IL-33. Intestinal ILC2s express ST2 but are known to be more sensitive to IL-25 than lung ILC2s. Nevertheless, mLN ILC2s were activated by IL-33 but do not express OX40L. Whether ILC2s are directly involved in regulating follicular T and B cell responses is an intriguing question, given our observation of reduced IgE concentrations in *Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^ mice after allergen or helminth exposure, and the known function of OX40 in humoral immunity ([@bib4], [@bib9], [@bib23], [@bib49]). Significantly, delineating the effect of OX40L expression by ILC2s and other immune cells in specific anatomical locations will aid the refinement of proposed immunotherapies targeting the OX40L/OX40 interaction ([@bib11], [@bib27]).

While important for establishing adaptive type 2 inflammation in the airways, we have not resolved the functional significance of the parallel ILC2-driven expansion of Treg cells. While Treg cells can suppress type 2 inflammation ([@bib26], [@bib36], [@bib48]), a more synergistic role is observed in cases of type 1 immune suppression, wound healing, and metabolism. This synergy, in addition to similarities in development, led to the hypothesis that Treg cell function can intersect with that of Th2 cells ([@bib2], [@bib40]). We indeed observed a substantial overlap in gene expression profiles between Th2 cells and Treg cells, but also ILC2s. Many of these genes such as *Irf4*, *Gata3*, *Nrp1*, *Areg*, and *Il1rl1* have shared functions between these lineages ([@bib1], [@bib34], [@bib38], [@bib46], [@bib54]). Moreover, lung GATA3^+^ Treg cells were strongly induced by protease allergens and IL-33, and our data support previous findings that assign enhanced effector function to this subset ([@bib58]). Further studies are required to dissect the IL-33-ILC2-OX40L axis on specific Treg cell subsets in homeostasis and disease.

In conclusion, we have revealed a critical immune-regulator checkpoint for tissue-specific orchestration of adaptive type 2 immunity, whereby the potent effect of the alarmin IL-33 on adaptive immunity is contingent on its upregulation of OX40L by ILC2s.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-mouse CD3εBiolegend100320; RRID: [AB_312685](nif-antibody:AB_312685){#intref0010}Anti-mouse CD4Thermo Fisher56-0041-82; RRID: [AB_493999](nif-antibody:AB_493999){#intref0015}Anti-mouse CD5Thermo Fisher48-0051-82; RRID: [AB_1603250](nif-antibody:AB_1603250){#intref0020}Anti-mouse CD8αBiolegend100750; RRID: [AB_2562610](nif-antibody:AB_2562610){#intref0025}Anti-mouse CD11bThermo Fisher48-0112-82; RRID: [AB_1582236](nif-antibody:AB_1582236){#intref0030}Anti-mouse CD11cThermo Fisher48-0114-82; RRID: [AB_1548654](nif-antibody:AB_1548654){#intref0035}Anti-mouse CD19Thermo Fisher48-0193-82; RRID: [AB_2043815](nif-antibody:AB_2043815){#intref0040}Anti-mouse CD45Biolegend103137; RRID: [AB_2561392](nif-antibody:AB_2561392){#intref0045}Anti-mouse CD127BD Bioscience562419; RRID: [AB_11153131](nif-antibody:AB_11153131){#intref0050}Anti-mouse Gr-1Thermo Fisher48-5931-82; RRID: [AB_1548788](nif-antibody:AB_1548788){#intref0055}Anti-mouse FcεR1αThermo Fisher48-5898-82; RRID: [AB_2574086](nif-antibody:AB_2574086){#intref0060}Anti-mouse Ter119Thermo Fisher48-5921-82; RRID: [AB_1518808](nif-antibody:AB_1518808){#intref0065}Anti-mouse Foxp3Thermo Fisher53-5773-82; RRID: [AB_763537](nif-antibody:AB_763537){#intref0070}Anti-mouse RORγtThermo Fisher46-6981-82; RRID: [AB_10717956](nif-antibody:AB_10717956){#intref0075}Anti-mouse GATA3Thermo Fisher50-9966-42; RRID: [AB_10596663](nif-antibody:AB_10596663){#intref0080}Anti-mouse NK1.1BD Bioscience56144Anti-mouse CTLA4Biolegend106305; RRID: [AB_313254](nif-antibody:AB_313254){#intref0085}Anti-mouse MHCIIThermo Fisher48-5321-82; RRID: [AB_1272204](nif-antibody:AB_1272204){#intref0090}Anti-mouse Ly6B (7/4)AbcamAb53453; RRID: [AB_881408](nif-antibody:AB_881408){#intref0095}Anti-mouse OX40Biolegend119409; RRID: [AB_2272150](nif-antibody:AB_2272150){#intref0100}Anti-mouse OX40LThermo Fisher12-5905-82; RRID: [AB_466036](nif-antibody:AB_466036){#intref0105}Anti-mouse TCRβThermo Fisher48-5961-82; RRID: [AB_11039532](nif-antibody:AB_11039532){#intref0110}Anti-mouse Neuropillin1Biolegend145204; RRID: [AB_2561928](nif-antibody:AB_2561928){#intref0115}Anti-mouse HeliosBiolegend137204; RRID: [AB_10549181](nif-antibody:AB_10549181){#intref0120}Anti-mouse Ki67Thermo Fisher25-5698-82; RRID: [AB_11220070](nif-antibody:AB_11220070){#intref0125}Anti-mouse Siglec-FBD Bioscience552126; RRID: [AB_39431](nif-antibody:AB_39431){#intref0130}Anti-mouse F4/80Thermo Fisher48-4801-82; RRID: [AB_1548747](nif-antibody:AB_1548747){#intref0135}Anti-mouse IL-13Thermo Fisher25-7133-82; RRID: [AB_2573530](nif-antibody:AB_2573530){#intref0140}Anti-mouse B220Thermo Fisher47-0452-82; RRID: [AB_1518810](nif-antibody:AB_1518810){#intref0145}Anti-mouse RELMαPeprotech500-p214; RRID: [AB_1268707](nif-antibody:AB_1268707){#intref0150}Anti-mouse CD3ε (eBio500A2)Thermo Fisher14-0033-82; RRID: [AB_837128](nif-antibody:AB_837128){#intref0155}Anti-mouse Foxp3 (TWAJ)Thermo Fisher53-9966-42; RRID: [AB_2574493](nif-antibody:AB_2574493){#intref0160}Anti-mouse CD127 (A7R34)Thermo Fisher17-1271-82; RRID: [AB_469435](nif-antibody:AB_469435){#intref0165}Anti-mouse IFNγBiolegend505837; RRID: [AB_11219004](nif-antibody:AB_11219004){#intref0170}Anti-human CD2Thermo Fisher17-0029-42; RRID: [AB_10805740](nif-antibody:AB_10805740){#intref0175}Anti-mouse ST2Thermo Fisher46-9333-82; RRID: [AB_2573881](nif-antibody:AB_2573881){#intref0180}Donkey anti-rat IgG FITCJackson ImmunoResearch712-095-150; RRID: [AB_2340651](nif-antibody:AB_2340651){#intref0185}Rabbit anti-FITC AF488Life TechnologiesA-11090; RRID: [AB_221562](nif-antibody:AB_221562){#intref0190}Donkey anti-rabbit IgG AF488Life TechnologiesA-21206; RRID: [AB_141708](nif-antibody:AB_141708){#intref0195}Anti-mouse CD40Thermo Fisher16-0401-82; RRID: [AB_468941](nif-antibody:AB_468941){#intref0200}IgG isotype controlBio X CellBE0085; RRID: [AB_1107771](nif-antibody:AB_1107771){#intref0205}Anti-human CD8αBiolegend301014; RRID: [AB_314132](nif-antibody:AB_314132){#intref0210}Anti-human CD11bBiolegend301309; RRID: [AB_314161](nif-antibody:AB_314161){#intref0215}Anti-human CD11cBiolegend337207; RRID: [AB_1279068](nif-antibody:AB_1279068){#intref0220}Anti-human CD123Biolegend306011; RRID: [AB_439778](nif-antibody:AB_439778){#intref0225}Anti-human CD20Biolegend302309; RRID: [AB_314257](nif-antibody:AB_314257){#intref0230}Anti-human CD56Biolegend318309; RRID: [AB_604098](nif-antibody:AB_604098){#intref0235}Anti-human CD71Biolegend334107; RRID: [AB_10916388](nif-antibody:AB_10916388){#intref0240}Anti-human FcεR1αBiolegend334612; RRID: [AB_10578086](nif-antibody:AB_10578086){#intref0245}Anti-human CD45Biolegend304023; RRID: [AB_493760](nif-antibody:AB_493760){#intref0250}Anti-human CD127Biolegend351335; RRID: [AB_2563636](nif-antibody:AB_2563636){#intref0255}Anti-human CRTH2Biolegend350105; RRID: [AB_10900255](nif-antibody:AB_10900255){#intref0260}Anti-human OX40LBiolegend326307; RRID: [AB_2207272](nif-antibody:AB_2207272){#intref0265}**Biological Samples**Fresh human PBMC obtained from healthy anonymous adult donors. No additional information is available, and was not required for the experimental design.N/AN/A**Chemicals, Peptides, and Recombinant Proteins**Recombinant mouse IL-25JanssenN/ARecombinant mouse IL-33Biolegend580508Recombinant mouse TSLPThermo Fisher34-8498-82Recombinant mouse TSLPR&D Systems555-TS-010Recombinant mouse IL-2Biolegend575406Recombinant mouse IL-7Biolegend577806Recombinant human IL-33Biolegend581802Recombinant human IL-2Biolegend589102Recombinant human IL-7Biolegend5819022W1S peptide (EAWGALANWAVDSA)Designer BioScienceN/AI-A(b) 2W1S tetramerNIH Tetramer CoreN/AFoxp3 intracellular staining kitThermo Fisher88-8008-74Protein transport inhibitor cocktailThermo Fisher00-4980-03Lipopolysaccharide (LPS)SigmaL3129-10MGAlternaria alternata extractGreer LaboratoriesAlternaria alternata, Alternaria tenuis (My1)PapainSigma76216Diphtheria toxinMerck322326-1MGDRAQ7Biolegend424001eFluor 780 viability dyeThermo Fisher65-0865-14eFluor 455 (UV) Viability dyeThermo Fisher65-0868-14Streptavidin AF555Life TechnologiesS32355LymphoprepSTEMCELL Tech07801TruStain FcXBiolegend422301M-280 DynabeadsThermo Fisher11205DO.C.T. compoundTissue-Tek23-730-571Collagenase ILife Technologies17100017DNase IQuiagen79254PercollSigmaGE17-0891-09UltraComp beadsInvitrogen01-2222-42Precision Count BeadsBiolegend424902BCA Protein Assay kitThermo23227Ovation Ultralow System V2 1-16Nugen0344NBOvation RNA-Seq System V2Nugen7102RNA 6000 Pico ChipAgilent5067-1513High sensitivity DNA ChipAgilent5067-4626**Critical Commercial Assays**Magpix array (IL-4, IL-5)MilliporeMCYTOMAG-70KCD4^+^ T cell enrichment kitMiltenyi130-104-453Murine IgE ELISAThermo Fisher88-50460-88**Deposited Data**RNA-seq dataThis paperGEO: [GSE112937](ncbi-geo:GSE112937){#intref0270}Microarray data (lung ILC2)[@bib15]GEO: [GSE36057](ncbi-geo:GSE36057){#intref0275}Microarray data (other)[@bib20]GEO: [GSE15907](ncbi-geo:GSE15907){#intref0280} and [GSE37448](ncbi-geo:GSE37448){#intref0285}**Experimental Models: Organisms/Strains**Mouse: C57BL/6 (B6)Charles River027Mouse: B6.*Rag2*^*−/−*^JAX008449; RRID: IMSR_JAX:008449Mouse: B6.*Il1rl1*^*−/−*^Dr. ANJ McKenzieN/AMouse: B6.iCOS-T (B6.*Icos*^*fl-DTR-fl/+*^*Cd4*^*Cre/+*^)Dr. ANJ McKenzie([@bib39])Mouse: B6.*Tnfrsf4*^*−/−*^Prof. P LaneN/AMouse: B6.*Il7r*^*Cre/+*^Prof. HR Rodewald([@bib44])Mouse: B6.*Il7r*^*Cre/+*^*Rora*^*fl/fl*^Dr. ANJ McKenzieN/AMouse: B6.*Rorc*^*Cre/+*^*Tnfsf4*^*fl/fl*^Dr. D WithersN/AMouse: B6.*Rorc*^*Cre/+*^Dr. D WithersN/AMouse: B6.*Tnfsf4*^*fl/fl*^Prof. M Botto and Prof. TJ Vyse([@bib4])Mouse: B6*.Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^Dr. ANJ McKenzieN/AMouse: B6.*Cd4*^*Cre*^*Tnfsf4*^*fl/fl*^Dr. ANJ McKenzieN/AMouse: B6.*Cd4*^*Cre*^Dr. ANJ McKenzieN/AMouse: B6*.Cd4*^*Cre*^*Rora*^*fl/fl*^Dr. SA TeichmannN/AMouse: B6*.Foxp3*^*DTR-egfp/+*^*Gata3*^*hCD2/+*^Dr. ANJ McKenzieN/AMouse: B6.Cg*-*^*Tg(Itgax-EGFP-CRE-DTR-LUC)2Gjh/Crl*^ (*Itgax*^*Cre/+*^)Prof. N GarbiN/AMouse: B6.*Itgax*^*Cre/+*^*Tnfsf4*^*fl/fl*^Dr. ANJ McKenzieN/AMouse: B6. *Ighm*^*tm1Cgn/J*^ (μMT)Dr. ANJ McKenzieN/AMouse: B6.*Il33*^*cit/cit*^ (*Il33*^*−/−*^)Dr. ANJ McKenzieN/A**Software and Algorithms**Flowjo V10FlowJo, LLC<https://www.flowjo.com/>FlexArray 1.5Genome Quebec<http://www.genomequebec.com/en/home.html>Partek FlowPartek<http://www.partek.com>Partek Genomics SuitePartek<http://www.partek.com>GraphPad Prism 7GraphPad Software, Inc<http://www.graphpad.com/scientific-software/prism/>

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Tim Halim (<tim.halim@cruk.cam.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### *In vivo* animal studies {#sec4.3.1}

C57BL/6 (B6), B6.*Il33*^*cit/cit*^ (*Il33*^*−/−*^), B6.*Il1rl1*^*−/−*^, B6.*Tnfrsf4*^*−/−*^, B6.*Il7r*^*Cre/+*^ ([@bib44]), B6.*Il7r*^*Cre/+*^*Rora*^*fl/fl*^, B6.*Rorc*^*Cre/+*^*Tnfsf4*^*fl/fl*^, B6.*Tnfsf4*^*fl/fl*^ mice ([@bib4]), B6*.Il7r*^*Cre/+*^*Tnfsf4*^*fl/fl*^, B6*.Foxp3*^*DTR-egfp/+*^, B6.*Cd4*^*Cre*^*Tnfsf4*^*fl/fl*^, B6*.Cd4*^*Cre*^*Rora*^*fl/fl*^, B6*.Foxp3*^*DTR-egfp/+*^*Gata3*^*hCD2/+*^ (B6.*Gata3*^*hCD2/+*^ mice, manuscript in preparation, J.A.W. and A.N.J.M), B6.Cg*-*^*Tg(Itgax-EGFP-CRE-DTR-LUC)2Gjh/Crl*^, B6.*Itgax*^*Cre/+*^*Tnfsf4*^*fl/fl*^, B6.iCOS-T (B6.*Icos*^*fl-DTR-fl/+*^*Cd4*^*Cre/+*^) ([@bib39]), B6. *Ighm*^*tm1Cgn/J*^, B6.*Rag2*^*−/−*^ and B6.*Rorc*^*Cre/+*^ mice were maintained in the Medical Research Council (MRC) ARES animal facility, under specific-pathogen-free conditions. Animals were sex and age matched whenever possible, and most animals were used at 6-10 weeks of age (we used OX40^*−/−*^ mice that were over 12 weeks old, which have normal Treg cell number during homeostasis ([@bib50]). All animal use was in accordance with the guidelines of the UK Home Office.

### Human studies {#sec4.3.2}

Peripheral blood samples were obtained from healthy anonymous adult donors after written informed consent was given. Whole blood was subjected to density centrifugation on Lymphoprep (STEMCELL Technologies) and peripheral blood mononucleated cells (PBMC) were collected from the interphase. All human work was approved by the appropriate UK research ethics committees (15/EE/0408).

### Primary cell culture {#sec4.3.3}

Human and mouse primary cells were cultured at 37°C in a humidified, 5% CO~2~ incubator.

Method Details {#sec4.4}
--------------

### Primary leukocyte preparation {#sec4.4.1}

Cell suspensions were prepared from lung by mechanical dissociation, followed by digest in 3 mL of RPMI-1640 containing collagenase I (500 U/ml) and DNase I (0.2 mg/ml) for 45 minutes at 37°C on a shaker (220 rpm), followed by filtration through a 70 μm strainer and 25% Percoll gradient enrichment of leukocytes and red blood cell (RBC) lysis. LN was strained through a 70 μm strainer with PBS, followed by RBC lysis. BAL cells and fluid were obtained in PBS as described ([@bib17]). Cell suspensions were prepared from perigonadal adipose tissue by mechanical dissociation, followed by digest in 1 mL of RPMI-1640 containing collagenase I (500 U/ml) and DNase I (0.2 mg/ml) for 45 minutes at 37°C on a shaker (1100 rpm), followed by filtration through a 70 μm strainer and RBC lysis. Cell suspensions were prepared from large intestine by initial cleaning with PBS (10 mM HEPES) and mechanical dissociation, incubation in EDTA/DTT to remove intraepithelial cells, followed by digest in 8 mL of RPMI-1640 (10 mM HEPES) containing Liberase (0.0625 mg/ml, Roche) and DNase I (0.2 mg/ml) for 30 minutes at 37°C on a shaker (200 rpm), followed by filtration through a 70 μm strainer and Percoll gradient enrichment of leukocytes and red blood cell (RBC) lysis. Single-cells were re-stimulated and stained for surface and intracellular markers as described below.

### Flow cytometry {#sec4.4.2}

Single cells were incubated with anti-mouse CD16/32 (Thermo Fisher) to block Fc receptors and stained as indicated. Lineage cocktail contained (±CD3, ± NK1.1, TCRβ, CD5, CD19, CD11b, CD11c, FcεR1α, F4/80, Ly-6C/G, and Ter119). For intracellular staining we used the Foxp3/Transcription Factor Kit (Thermo Fisher). For intracellular cytokine detection, single cells were stimulated with PMA (60 ng/ml) and ionomycin (500 ng/ml) and 1X protein transport inhibitor (Thermo Fisher) in culture media (RPMI-1640, 10% FCS) at 37°C for 3 hours before staining. Flow cytometry analysis was performed on a BD Fortessa instrument. Cells were quantified using CountBright beads or manual cell counting by hemocytometer. Flow cytometry data was analyzed using FlowJo X (Tree Star).

### *In vivo* stimulation {#sec4.4.3}

Mice were anesthetized by isofluorane inhalation, followed by the intranasal administration of rmIL-25 (0.2 μg), rmIL-33 (0.2 μg), rmTSLP (0.2 μg), LPS, *Alternaria alternata* extract (10 μg, Greer Laboratories), or papain (10 μg) in 40 μl of PBS. Diphtheria toxin (300--500 ng), anti-CD40 mAb or IgG control (100 μg), or rmIL-33 (0.5 μg) was administered by intraperitoneal injection in 200 μl PBS. For *Nippostrongylus brasiliensis* infections 500 live L3 larvae were injected subcutaneously in 100 μl of water.

### Adoptive CD4^+^ T cell transfer {#sec4.4.4}

CD4^+^ T cells were enriched from naive B6 and B6.*Il1rl1*^*−/−*^ mice using a magnetic bead negative selection strategy (Miltenyi Biotech). CD4^+^ T cell enriched cells were quantified and equal numbers of each genotype was adoptively transferred to CD45.1 congenic B6.*Rag2*^*−/−*^ recipient mice on day −5. Adoptively transferred mice where subsequently used as indicated.

### Bone marrow transplantation {#sec4.4.5}

Recipient mice were lethally irradiated (2 doses of 4.5 Gy) followed by intravenous transplantation of 10^7^ whole bone marrow cells from 4-6 week old mice. Mice were given Baytril in drinking water for 4 weeks, and used for analysis at 24-32 weeks post transplant.

### IF microscopy {#sec4.4.6}

Lungs were infused with 50% O.C.T. (Tissue-Tek) in PBS immediately after mice were killed. Lungs were subsequently frozen in 100% O.C.T. compound, followed by sectioning. 6 μm-thick sections of frozen lung tissue were cut, fixed in cold acetone at 4 °C for 20 min and then stored at −20 °C before staining. Antibodies raised against the following mouse antigens were used: CD3 (biotinylated, clone eBio500A2, Thermo Fisher), FoxP3 (APC conjugated, clone FJK-16 s, Thermo Fisher), GATA-3 (unconjugated, clone TWAJ, Thermo Fisher), IL-7Rα (efluor660 conjugated, clone A7R34, Thermo Fisher). Detection of GATA-3 expression required amplification of the signal: the primary antibodies were detected with donkey anti-rat-IgG-FITC (Jackson ImmunoResearch), then rabbit anti-FITC-AF488 (Life Technologies) and then with donkey anti-rabbit-IgG-AF488 (Life Technologies). Biotinylated anti-CD3 antibodies were detected with SA-AF555 (Life Technologies). Sections were counterstained with DAPI (Invitrogen) and mounted using ProLong Gold (Invitrogen). Slides were analyzed on a Zeiss 780 Zen microscope (Zeiss).

### Histology {#sec4.4.7}

All mouse lung lobes were weighed and a single lobe was used for histology. Lung lobes were fixed in 10% formaldehyde in PBS for 24 hours at 4°C, followed by transfer to 70% Ethanol in PBS for 24 hours at 4°C. Finally, lung lobes were transferred to PBS and kept at 4°C until paraffin embedding. Sections were cut and stained with Mason's trichrome reagent. The CRUK Cambridge Institute Histology Core performed tissue embedding, sectioning and staining.

### Human ILC2 culture {#sec4.4.8}

PBMC were blocked with TruStain FcX and stained with biotinylated αCD3, αCD14 and αCD19 for the depletion of T cells, monocytes and B cells by MACS using M-280 streptavidin Dynabeads (Thermo Fisher), according to the manufacturer's instructions. Following further antibody staining, ILC2 were sorted from depleted PBMC based on surface marker expression as lineage negative (streptavidin-APC, CD8a, CD11b, CD11c, FcεRIα, CD123, CD20, CD56, CD71), DRAQ7^-^, CD45^+^, CD127^+^ and CRTH2^+^ on a BD Influx. Sorted ILC2 were cultured in RPMI (GIBCO) supplemented with 10% FBS, 100 μM 2-mercaptoethanol, 100 μg/mL penicillin, 100 IU/mL streptomycin, 20 mM HEPES and 10 ng/mL recombinant human IL-2, IL-7 and IL-33 (as indicated). OX40L surface protein expression was assessed by flow cytometry after 72 hours of culture. Briefly, following Fc-receptor blocking, ILC2 were stained with lineage antibodies (CD3, CD11b, CD19), OX40L and efluor780 fixable viability dye followed by acquisition on a BD LSR Fortessa flow cytometer. Data was analyzed with FlowJo 10.2.

### Gene expression analysis {#sec4.4.9}

We obtained microarray datasets for the listed cell-types (T.8Nve.Sp1/2, T.4Nve.SP5/6, T.4Mem4h62l.Sp1.2, T.4FP3+25+.Sp2/3, B.Fo.Sp, MC.PC4/5, MF.11c-11b+.Lu, Mo.6C-II-Lu.v2, DC.103-11b+24+.Lu, GN.Bl, Eo.BL.v2, NKT.4+.SP1/2, NK.Sp7/8, ILC1.CD127+.SP1/2, BA.SP1/3, LPL.NCR+ILC3.1/2,) from data assembled by the ImmGen consortium ([@bib20]), which was compared to our own lung ILC2 microarray data ([@bib15]). Data analysis was performed with FlexArray 1.5 (Genome Quebec).

### IgE measurement {#sec4.4.10}

Lungs were frozen in liquid nitrogen, then homogenized in PBS protein inhibitor (cOmplete EDTA free protease inhibitor tablets, Roche), centrifuged to remove cell debris and supernatants were harvested. Total lung protein was measured using a BCA assay (Thermo Fisher) and Lung and serum IgE concentrations were measured by ELISA assay (Thermo Fisher).

### RNA-seq {#sec4.4.11}

Foxp3^egfp+^GATA3^hDC2+^ mice were treated with nothing or rmIL-33 (0.2 μg) in PBS (i/n, day 0 and 1) followed by collection of lung tissue on day 5. Single cells were incubated with anti-mouse CD16/32 to block Fc receptors and stained with DAPI, anti-CD45, CD3, CD4, B220, Lineage (NK1.1, Gr-1, CD11b, CD11b, Ter119, CD19, CD5, F4/80, FcεR1α), and hCD2 mAb, followed by sorting of: DAPI (Live)^−^ CD45^+^ B220^−^ into CD3^+^ CD4^+^ eGFP(Foxp3)^+/−^ hCD2(Gata3)^+/−^ T cells, and DAPI(Live)^−^ CD45^+^ B220^−^ Lineage^−^ CD3^−^ CD4^−^ hCD2(Gata3)^+^ ILC2. CLP were sorted from the bone marrow as CD45^+^ Lineage^−^ Sca-1^int^ CD127^+^ Flt3^+^ cells. Cells were flow sorted into PBS 2% FCS and transferred to Trizol LS (Life Technologies). chloroform extractions were performed and 1.5X volume of 100% ethanol was added to the aqueous phase. RNA was extracted using RNeasy kit (QIAGEN), gDNA was digested using Turbo DNase (Ambion), concentrated using RNeasy Micro Kit (QIAGEN) and assessed using the Bioanalyser (Agilent). RNA was processed for RNA sequencing using Ovation RNA-seq System V2 (Nugen), fragmented using the Covaris M220 and barcoded using Ovation Ultralow Library Systems (Nugen). Samples were sequenced using the Illumina Hiseq4000 (CRUK Cambridge Institute) and aligned using Tophat2 with Partek Flow. RPKM and differential gene transcript expression were generated using Genomics Suite^®^ software, version 6.16 Copyright ©; 2016 Partek^®^ Inc., St. Louis, MO, USA.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Statistics {#sec4.5.1}

Data were analyzed using GraphPad Prism 6 (GraphPad Software). A Kruskal-Wallis one-way ANOVA with Bonferroni post-analysis, or two-tailed Student's t test was used to determine the statistical significance between groups with p ≤ 0.05 being considered significant (^∗^), p ≤ 0.01 = ^∗∗^, p ≤ 0.001 = ^∗∗∗^, p ≤ 0.0001 = ^∗∗∗∗^.

### Additional details for main figures {#sec4.5.2}

[Figure 1](#fig1){ref-type="fig"}**:** (**A-C**, 3 repeat experiments, mean % gated population in **A**), (**D**, single experiment), (**E**, n = 4,4,4,4 left to right, ANOVA, 3 repeat experiments), (**F**, n = 5,5,5 left to right, ANOVA, 2 repeat experiments), (**G**, n = 4,4,4,4 left to right, ANOVA, 3 repeat experiments)

[Figure 2](#fig2){ref-type="fig"}**:** (**A**, 2 independent datasets per group), (**B-C**, n = 5,5,5,5 left to right in **C**, ANOVA, 2 repeat experiments), (**D-F**, n = 10,9,10 left to right in **D**, n = 10,10,10 in **E** and **F**, ANOVA, 2 pooled repeat experiments), (**G-I**, n = 5,5,5 left to right, ANOVA, 2 repeat experiments)

[Figure 3](#fig3){ref-type="fig"}**:** (**A**, 2 independent datasets per group), (**B**, n = 3, mean percent gated shown ± S.D., 3 repeat experiments), (**C**, n = 3,3,3,3,3,3 left to right, ANOVA, 2 repeat experiments), (**D**, n = 4,4,4 left to right, ANOVA, 2 repeat experiments), (**E**, n = 4, percent gated shown ± SD two-tailed Student's t test, 2 repeat experiments)

[Figure 4](#fig4){ref-type="fig"}: (**A**, n = 4,4,4 left to right, percent gated shown ± S.D., 3 repeat experiments), (**B-D**, n = 4,8,8,8 left to right for **B** and **C** n = 4,4,4,4 left to right for **D**, ANOVA, 2 repeat experiments), (**E-G**, n = 5,5, percent gated shown ± SD for **E**, n = 8,8,8,8 for **F** and **G** (n = 8,8,8,7 for Adipose), ANOVA, 2 pooled repeat experiments)

[Figure 5](#fig5){ref-type="fig"}**:** (**A**, n = 10,10,10 left to right, ANOVA, 2 pooled repeat experiments), (**B**, n = 10,10,10 left to right, ANOVA, 2 pooled repeat experiments), (**C**, n = 5,5,5 left to right, ANOVA, 2 repeat experiments), (**D** and **E**, n = 10,10,10 left to right, ANOVA, 2 pooled repeat experiments)

[Figure 6](#fig6){ref-type="fig"}**:** (**A-D**, n = 5,5,5,3,5 left to right, ANOVA, 2 repeat experiments), (**E**, n = 11,9,10 left to right, ANOVA, 3 repeat experiments (2 pooled experiments shown)), (**F-G**, n = 5,4,5 left to right, ANOVA, 2 repeat experiments, representative gate shown in **F**), (**H-I**, n = 5,5,5 left to right, ANOVA, 2 repeat experiments)

[Figure 7](#fig7){ref-type="fig"}**:** (**A-C**, n = 10,10,10,10 left to right, ANOVA, 3 repeat experiments (2 pooled experiments shown)), (**D**, 2 repeat experiments), (**E-I**, n = 5,5,5,5 left to right, ANOVA, 2 repeat experiments), (**J-L**, n = 10,10,10,10 left to right, ANOVA, 3 repeat experiments (2 pooled experiments shown)), (**M**, n = 5,5,5,5 left to right, ANOVA, 2 repeat experiments), (**N**, n = 10,13 left to right, two-tailed Student's t test, 2 pooled experiments)

Data and Software Availability {#sec4.6}
------------------------------

Microarray datasets for ILC2 are available under accession number [GSE36057](ncbi-geo:GSE36057){#intref0320}; all other microarray datasets are available under [GSE15907](ncbi-geo:GSE15907){#intref0325} and [GSE37448](ncbi-geo:GSE37448){#intref0330}. RNA-seq datasets are available in GEO ([GSE112937](ncbi-geo:GSE112937){#intref0335}).
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